About BioD
BioD is a Healthcare company based in Memphis (United States) founded in 2010, and was acquired by Derma Sciences in July 2016. Novel biologic products from placental tissues are developed and commercialized. Its focus areas include Life Sciences, Regenerative Medicine, Biomaterials and Scaffolds. Its competitors include Humacyte, Solsys Medical and Derma Sciences; 3 of its 3 listed competitors have raised funding.
Company details
BioD is a vertically integrated biotechnology company engaged in the development and commercialization of novel biologic products derived from the placental tissues. Their research and development efforts are focused on the regenerative potential of amnion and the other placental tissues given their unique biologic structure, their rich source of undifferentiated stem cells, and the immune privilege that characterizes their function in the body. From the recovery of tissue from live, healthy donors during childbirth to the development of new products that improve patient outcomes, BioD is unlocking the regenerative potential of the human body. BioDs product portfolio consists of human placental tissue-derived allografts for a broad range of clinical applications, including the treatment of complex chronic wounds, acute wounds (for example, decubitus or pressure ulcers), and localized areas of injury or inflammation, in addition to filling soft tissue defects or voids.. The products are also used as a localized wound covering to minimize the formation of post-operative adhesions, as well as to cover or wrap the dura, nerves and tendons.
- Headquarters Memphis, United States
- Stage Acquired
- SectorsHealthcare
- Website biodlogics.com
- Social LinkedIn X
- Acquired by Derma Sciences (Jul 2016)
- Investors
- Acquired byDerma Sciences
(Jul 2016)
Investors in BioD
BioD has secured backing from 1 investor. Prominent investors backing the company include Derma Sciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of tissue regeneration and wound care products | 1984 | dermasciences.com | Princeton, United States |
Investor details for BioD
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of BioD
2 dated milestones of BioD across 6 years, from founding to its latest funding, stage changes and deals.
- Founded BioD is founded.
- Exit Acquired by Derma Sciences.
Competitors of BioD
BioD has 3 listed competitors in our database, 3 of them funded. They include Humacyte, Solsys Medical and Derma Sciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| humacyte.com | 2004 | Morrisville, United States | $424.76M | 70 | Human tissue-based products are developed for vascular disease applications. | |
| solsysmedical.com | 1999 | Norfolk, United States | $29.55M | Human skin allografts and dressings for wound care are supplied. | ||
| dermasciences.com | 1984 | Princeton, United States | $16.16M | 123 | Developer of tissue regeneration and wound care products |
Detailed competitors of BioD
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of BioD
Websites that share an audience with BioD (biodlogics.com).
Websites whose visitors overlap most with BioD. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| facebook.com | 100% | 12.1B | #3 | View details | |
| google.com | 100% | 85.8B | #1 | View details |
Top companies in Wound Care
3 companies that operate in the same segment as BioD (Wound Care) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanotech-based wound care products are developed and provided. | 2010 | Madison, Wisconsin, United States | USD 22.7 M | 35 | ||
Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics | 1985 | Marietta, Georgia, United States | USD 418.63 M | 837 | ||
Developer of hemostatic products for wound care | 2010 | New York, New York, United States | USD 113.35 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biod
Complete news archive for BioD
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioD
BioD was founded in 2010.
BioD is headquartered in Memphis, United States. It is registered at Memphis, Tennessee, United States.
BioD is a vertically integrated biotechnology company engaged in the development and commercialization of novel biologic products derived from the placental tissues. Their research and development efforts are focused on the regenerative potential of amnion and the other placental tissues given their unique biologic structure, their rich source of undifferentiated stem cells, and the immune privilege that characterizes their function in the body. From the recovery of tissue from live, healthy donors during childbirth to the development of new products that improve patient outcomes, BioD is unlocking the regenerative potential of the human body. BioDs product portfolio consists of human placental tissue-derived allografts for a broad range of clinical applications, including the treatment of complex chronic wounds, acute wounds (for example, decubitus or pressure ulcers), and localized areas of injury or inflammation, in addition to filling soft tissue defects or voids.. The products are also used as a localized wound covering to minimize the formation of post-operative adhesions, as well as to cover or wrap the dura, nerves and tendons.
BioD's top competitors include Humacyte, Solsys Medical and Derma Sciences.
BioD has 1 investor. Key investors include Derma Sciences.
Yes. BioD was acquired by Derma Sciences in July 2016.